Helene McHale
Nurse Practitioner · Annapolis, MDNPI 1538678826
Payments from drug & device makers
Across 41 payments — averaging $26.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$107
- Novartis$83
- Takeda Pharmaceuticals U.S.A., Inc.$82
- Daiichi Sankyo Inc.$76
- Johnson & Johnson$69
- Regeneron Healthcare Solutions, Inc.$63
- plus $616 from 21 others
What the payments were for
- Food & beverage$1,096100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 3 | $107 |
| Novartis | 3 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $82 |
| Daiichi Sankyo Inc. | 3 | $76 |
| Johnson & Johnson | 3 | $69 |
| Regeneron Healthcare Solutions, Inc. | 2 | $63 |
| Bristol Myers Squibb | 2 | $58 |
| Incyte Corporation | 2 | $48 |
| Genentech USA, Inc. | 2 | $44 |
| Bayer | 2 | $37 |
| Coherus Oncology, Inc. | 2 | $35 |
| Taiho Oncology, Inc. | 1 | $33 |
| Pharmaessentia USA Corporation | 1 | $33 |
| Genmab U.S., Inc. | 1 | $32 |
| AstraZeneca | 1 | $29 |
| Array Biopharma Inc | 1 | $28 |
| AbbVie | 1 | $27 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Caris MPI, Inc. | 1 | $23 |
| Eisai Inc. | 1 | $23 |
| Organon | 1 | $22 |
| Sobi, Inc | 1 | $22 |
| Acrotech Biopharma Inc. | 1 | $22 |
| GSK | 1 | $21 |
| Spectrum Pharmaceuticals Inc. | 1 | $20 |
| Pfizer | 1 | $20 |
| Tempus AI, Inc | 1 | $15 |
How this compares
$1,096 in reported general payments places this provider in the 85th percentile of 1,562 nurse practitioner providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 65 | $66,617 |
| XareltoRivaroxaban | 26 | $27,342 |
| Anastrozole | 61 | $1,337 |
| Hydroxyurea | 18 | $307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $20 | $66,61765 claims |
| Johnson & JohnsonXarelto | $69 | $27,34226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,562 nurse practitioner providers in Maryland.
Other nurse practitioner in Annapolis
- Martha ReilleyAnnapolis$18K
- Stephanie ZwonitzerAnnapolis$16K
- Diane SchmidtAnnapolis$9K
- Morgan GaleRockville$292K
- Sherilyn BrinkleyBaltimore$100K
- Michelle TurnerBaltimore$94K
- Nelli ZafmanLutherville$67K
- Ellen LancasterFallston$52K
- Doris TateEaston$34K
- Zeev NemirovskyBaltimore$19K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.